Morgan Stanley now holds the most pessimistic view of Novo Nordisk's (NVO) stock. It downgraded the company to underweight from equal weight and set a Street-low price target of $47. Marley Kayden talks about how the company's Alzheimer trials for one of its treatments played a key role in the downgrade. Prosper Trading Academy's Charles Moon goes against the tide and explains why he sees short-term potential through an example options trade.